relaxants used during surgery will get priority review from U.S. regulators. Schering acquired sugammadex as part of its November purchase of Akzo Nobel NV’s Organon division, the company said in a statement today. A priority review by the U.S. Food and Drug Administration reduces the approval process to six months from at least 10.
Sugammadex reverses the effects of rocuronium bromide and vecuronium bromide, muscle relaxants regularly used under general anesthetic. If approved, the drug will be the first in a new class that helps patients to recover movement more quickly after surgery.
